Clean Tech Co.'s 'Forever Chemical' Solution Is a PFAS Breakthrough
Biotech Secures FDA Alignment on Late-Stage Duchenne Therapy
Biotech Battles FDA, Target Price Shows Potential 90% Gains
Research Report
Pharma's Flu Drug Could Be Worth Billions, Analyst Says
Research Report
Biotech Discovers Breakthrough DMD Therapy Opportunity
Research Report
Seeking Formulation of New Drug, Biopharma Co. Signs LOI
Research Report
Healthcare Firm Targets Alzheimer's With Technology Breakthrough
New Remission Data on MG Patients Compelling
Research Report
Kyverna Therapeutics Inc.'s (KYTX:NASDAQ) KYV-101 cell therapy drives a 15-month and longer remission in three patients treated on a compassionate use basis, noted an H.C. Wainwright & Co. report. Cell Therapy Firm Kyverna Advances U.S. Phase 3 MG Trial
Kyverna Therapeutics Inc. (KYTX:NASDAQ) unveiled the design of its U.S. registrational Phase 3 trial for KYV-101 in myasthenia gravis during a Key Opinion Leader event, following ≥ 15-month remission data in Germany. Read more to see what sets this trial apart.Biopharma Firm Accelerates AI-Driven Cancer Drug Discovery in Canada
Rakovina Therapeutics Inc. (RKV:TSX.V) secured fresh funding, advanced preclinical PARP and ATR programs, and leveraged exclusive AI platforms to target DNA-repair pathways. Read more for insight into its expanding role in precision oncology.Healthcare AI Company Rebrands as Rocket Doctor AI to Pursue Growing Market Opportunities
Treatment.com AI Inc. has rebranded and reincorporated as Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) to reflect the integration of its proprietary AI-driven Global Library of Medicine (GLM) with the recently acquired Rocket Doctor Inc. Read why one analyst calls part of the company's offerings "Shopify for physicians." This article is issued on behalf of Rocket Doctor AI AI Healthcare Stock Showing Signs of a Base Breakout
Contributed Opinion John Newell of John Newell & Associates explains why he thinks Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) is a Speculative Buy.
Co.'s Graphene Used in New Screening Test for Lung Cancer
HydroGraph Clean Power Inc.'s (HG:CSE; HGRAF:OTCQB; M98:FSE) patented, high-purity material has applications in healthcare, as in this case, but also in numerous other industries. Read on to learn why some experts say this company could be a future 100-bagger.Medical Co.'s New Joint Venture Could Expand Co.'s Footprint
Research Report
Leede Financial Inc. analyst Dr. Douglas Loe gave this company a Buy rating. Canadian Pharmaceutical Company Discovers Breakthrough Cardiovascular Treatment
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) announces topline results from its Phase II clinical study involving patients with acute myocarditis. Read why analysts like this pharmaceutical stock.Pharmaceutical Company Discovers Breakthrough Heart Treatment in Canada
Research Report
Top-line results from Cardiol Therapeutics' (CRDL:TSX; CRDL:NASDAQ) ARCHER study for Acute Myocarditis are quite promising, writes Roth Capital Partners Analyst Jason Wittes in an updated research note. 
Streetwise Key Charts
